米诺地尔
毛发移植
医学
脱发
毛发生长
非那雄胺
皮肤病科
药方
移植
头发周期
外科
生理学
头皮
药理学
内科学
前列腺
癌症
作者
Marc R. Avram,John P. Cole,Chevy Chase,Marcelo Gandelman,Róbert Haber,Russell Knudsen,Matt Leavitt,Robert T. Leonard,Carlos J. Puig,Paul T. Rose,James E. Vogel,Craig Ziering
出处
期刊:Dermatologic Surgery
[Lippincott Williams & Wilkins]
日期:2002-10-01
卷期号:28 (10): 894-900
被引量:38
标识
DOI:10.1046/j.1524-4725.2002.02068.x
摘要
BACKGROUND Over the last decade surgical management of hair loss has become an increasingly popular and satisfying procedure for both men and women, as innovations in donor harvesting, graft size, and hairline design have resulted in consistently natural-appearing hair restoration. OBJECTIVE In addition, a better understanding of the regulation of the hair-growth cycle has led to advances in the pharmacologic treatment of androgenetic alopecia. METHODS Currently there are two U.S. Food and Drug Administration (FDA)-approved agents that promote hair regrowth: over-the-counter topical minoxidil solution for men and women and prescription oral finasteride tablets for men. In October 2001, a group of 11 international experts on hair loss and hair transplantation convened to review the physiology and effects of pharmacologic treatments of hair loss and to discuss the value of administering topical minoxidil therapy as an adjunct to hair transplantation. RESULTS This article presents the key findings and consensus points among the participants, including their current use of pharmacologic treatments, strategies for optimal results both pre- and postsurgery, and the importance of realistic patient expectations and compliance. conclusions Based on the surgeons' clinical experience, the use of approved hair regrowth agents in hair transplant patients with viable but suboptimally functioning follicles in the region to be transplanted can increase hair density, speed regrowth in transplanted follicles, and complement the surgical result by slowing down or stopping further hair loss.
科研通智能强力驱动
Strongly Powered by AbleSci AI